Embedded Files
We aim to understand cancer from its physical properties and offer new ways for treatments
We aim to understand cancer from its physical properties and offer new ways for treatments
The challenge
Cancer is one of the most life-threatening diseases. Research has been actively conducted on cancer for decades, yet this disease persists as very difficult to cure. Distinct cancer types are characterized and driven by a wide variety of gene mutations. Despite each harboring its own set, they inevitably converge on shared features and properties. Current gene-based therapies aim to cure cancer by repairing or restoring mutated genes, but these approaches have not shown beneficial effects. Chemical drugs that inhibit proliferation pathways often lead to drug resistance. Immunotherapies have limited effectiveness in the majority of solid tumors. In light of these challenges, we present a new approach to treating cancers by identifying deviations in their physical states from those of normal cells.
Company Overview
ACA Biotech LLC (the "Company") is an early-stage biotechnology company focused on developing a new class of computational and biologically guided cancer therapeutics. The Company's origins lie in the recognition that a cell, much like a mechanical or thermal system, operates according to definable physical principles and states. The Company’s mission is to integrate principles from computational biology and physical science to better understand how cancer cells deviate from normal cellular states and to translate these insights into novel therapeutic strategies.
Our Solution: Restoration of cellular state
Through years of study, we found that cancers deviate from their normal counterparts in their physical states. There are key state contributors in each cancer type and in each patient that drive towards the disease's physical states. We have developed two computational methods that can uniquely identify and characterize these specific state contributors. The ability to identify these key contributors in each patient allows us to:
Find specific and unique contributors that determine the state aberrancy in each individual;
Guide making “State-correction” Constructs for restoring physical states;
Apply these “State-correction” Constructs in vivo to repair the cancer cell states back to normal ones.
The global market for genomic and multi-omics data platforms is experiencing rapid growth. It is estimated to grow from USD 4.84 billion in 2025 to USD 20.01 billion by 2034.
The global shift toward precision medicine necessitates advanced computational tools to translate raw genomic data into deep insights to better understand cancer mechanisms and potential treatments.
What do we offer
With specialized expertise and commitment, we utilize our own algorithms to offer a comprehensive, customized interpretation and analysis report of the omics data provided by our customers. We aim to translate raw genomic data into deep insights to better understand cancer mechanisms and potential treatments. By combining expertise in physical sciences with modern genomic data analysis, ACA Biotech seeks to create innovative tools and therapeutic strategies that can help researchers and biotechnology partners uncover new ways to understand and treat cancer.
Active Research Initiatives
We have conducted extensive research and development phase for several years for our products and solutions. We are actively partnering with leading academic institutes to generate specialized lists of state contributors pertaining to individual cancer types and individual patients based on our algorithms. Next, we will apply the results given by our algorithms to conduct cellular and animal experiments to validate our approach.
Join us to accelerate your career
Join us to accelerate your career
Our team
Our team
Xiaoping Wu, Ph.D., President and Founder Mechanical-Thermal scientist with 20+ years of experience
ACA Biotech LLC
9700 Heathermill Lane, Raleigh, NC 27617, USA
T: +1 6072800382
© 2026 ACA Biotech LLC. All Rights Reserved.
Page updated
Google Sites
Report abuse